Overview
SCIENTIFIC SCORE
Questionable
Based on 29 Researches
6.8
USERS' SCORE
Good
Based on 1 Review
8.4
Top Medical Research Studies
8
We examined the relationship between vitamin D intake and breast cancer, delving into how this vitamin may play a role in prevention and management. The findings suggest that vitamin D may have a protective effect, potentially lowering the risk of developing breast cancer.
While we found a notable connection, it’s important to recognize that most of the existing evidence comes from observational studies. This means we can identify associations but cannot definitively say that vitamin D causes these effects.
Additionally, there are several complexities in studying vitamin D, such as varying metabolism and differences in study designs, which make drawing firm conclusions challenging.
Although the research provides intriguing insights, more rigorous studies are necessary to truly clarify how vitamin D could be integrated into breast cancer care moving forward.
While we found a notable connection, it’s important to recognize that most of the existing evidence comes from observational studies. This means we can identify associations but cannot definitively say that vitamin D causes these effects.
Additionally, there are several complexities in studying vitamin D, such as varying metabolism and differences in study designs, which make drawing firm conclusions challenging.
Although the research provides intriguing insights, more rigorous studies are necessary to truly clarify how vitamin D could be integrated into breast cancer care moving forward.
Read More
8
Vitamin D impacts breast cancer outcomes
We explored how vitamin D (VD) levels might impact breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NACT). The study reviewed data from six different research projects involving patients who had confirmed diagnoses of BC and had their vitamin D levels measured before starting chemotherapy.
Our analysis revealed some intriguing findings. Specifically, maintaining adequate vitamin D levels appeared to lower the chances of not responding to neoadjuvant chemotherapy by 22%. Additionally, those with sufficient vitamin D experienced a 35% reduced risk of disease progression compared to those with low or deficient levels. This suggests that vitamin D might play a beneficial role in improving treatment outcomes for breast cancer patients.
Overall, these results underscore the importance of keeping vitamin D levels within a healthy range during cancer treatment. They encourage us to delve deeper into how vitamin D influences cancer biology and its potential as a supportive therapy in breast cancer management.
Our analysis revealed some intriguing findings. Specifically, maintaining adequate vitamin D levels appeared to lower the chances of not responding to neoadjuvant chemotherapy by 22%. Additionally, those with sufficient vitamin D experienced a 35% reduced risk of disease progression compared to those with low or deficient levels. This suggests that vitamin D might play a beneficial role in improving treatment outcomes for breast cancer patients.
Overall, these results underscore the importance of keeping vitamin D levels within a healthy range during cancer treatment. They encourage us to delve deeper into how vitamin D influences cancer biology and its potential as a supportive therapy in breast cancer management.
Read More
5
Vitamin D's impact on muscle strength
We explored the connection between vitamin D levels and muscle strength in women with breast cancer. This research involved adult women who had been diagnosed with breast cancer within the last 12 months, ensuring that none had metastases or recurrences. Our focus was on understanding how inadequate vitamin D might relate to reduced muscle strength in this specific group.
We discovered that a significant portion of the participants, around 70%, had insufficient levels of vitamin D. This deficiency was notably linked to lower muscle strength, as indicated by the Handgrip Strength test. Specifically, the findings showed that women with insufficient vitamin D were more likely to fall into the lower muscle strength categories.
The study sheds light on the importance of monitoring vitamin D levels in women battling breast cancer. Given the link between low vitamin D and weaker muscle strength, addressing this deficiency might offer a new avenue for improving overall health and vitality in these patients.
We discovered that a significant portion of the participants, around 70%, had insufficient levels of vitamin D. This deficiency was notably linked to lower muscle strength, as indicated by the Handgrip Strength test. Specifically, the findings showed that women with insufficient vitamin D were more likely to fall into the lower muscle strength categories.
The study sheds light on the importance of monitoring vitamin D levels in women battling breast cancer. Given the link between low vitamin D and weaker muscle strength, addressing this deficiency might offer a new avenue for improving overall health and vitality in these patients.
Read More
Most Useful Reviews
7.5
Side effects manageable
4 people found this helpful
I read about vitamin D possibly reducing the side effects of the drug Arimidex (anastrozole), which I take daily for estrogen-positive breast cancer. My oncologist is pleased that I am managing the side effects, and I believe that taking 5000 IUs of Vitamin D3 daily contributes to that. Some women in my support group have had to stop Arimidex due to side effects, so I hope this helps me prevent that. I am 65 days in and tolerating it well, which is reassuring given my previous chemotherapy side effects. Always consult with your doctor, of course.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 29 Researches
6.8
- All Researches
9
We set out to explore how Vitamin D3, when combined with gold nanoparticles (VD3-GNPs), could influence breast cancer's aggressiveness. Our research focused on breast cancer cell lines, specifically MCF-7 and MDA-MB-231, to see if this innovative treatment could significantly reduce cancer cell migration and invasion.
Through a series of methods including Western blots and migration/invasion assays, we observed that the VD3-GNP treatment led to an impressive reduction in cancer aggressiveness, with migration and invasion rates dropping by over 45%. This effect seems to come from the downregulation of key pathways associated with cancer growth and spread, namely the PI3K/AKT/mTOR pathway, as well as ETV7 and the Hippo pathway.
What's particularly surprising is the fact that we achieved these results using a relatively low dose of Vitamin D3—three orders of magnitude lower than doses used in past studies. This makes VD3-GNPs an appealing option for non-toxic and cost-effective treatments aimed at combating breast cancer's aggressive nature.
Through a series of methods including Western blots and migration/invasion assays, we observed that the VD3-GNP treatment led to an impressive reduction in cancer aggressiveness, with migration and invasion rates dropping by over 45%. This effect seems to come from the downregulation of key pathways associated with cancer growth and spread, namely the PI3K/AKT/mTOR pathway, as well as ETV7 and the Hippo pathway.
What's particularly surprising is the fact that we achieved these results using a relatively low dose of Vitamin D3—three orders of magnitude lower than doses used in past studies. This makes VD3-GNPs an appealing option for non-toxic and cost-effective treatments aimed at combating breast cancer's aggressive nature.
Read More
9
Vitamin D3 enhances breast cancer treatment
We aimed to understand how vitamin D3 influences breast cancer treatment by testing it alongside doxorubicin (Dox) and probiotics using a group of mice. The study involved female BALB/c mice that were divided into various groups to see how these treatments affected tumor growth and overall health compared to a control group.
Our findings showed that the combinations of Dox with vitamin D3 and probiotics significantly reduced tumor size and weight, indicating that vitamin D3 may enhance the effectiveness of breast cancer chemotherapy. The study also found that these combinations had protective effects against the toxicity typically caused by Dox. Especially notable was the increase in genes associated with tumor reduction and a decrease in those linked to cancer cell survival.
However, it’s essential to note that this study focused on the combined effects of vitamin D3, probiotics, and Dox, which makes it challenging to isolate the specific impact of vitamin D3 alone on breast cancer outcomes. Overall, the results suggest that incorporating vitamin D3 into breast cancer treatment protocols could be beneficial, particularly in combination with other agents.
Our findings showed that the combinations of Dox with vitamin D3 and probiotics significantly reduced tumor size and weight, indicating that vitamin D3 may enhance the effectiveness of breast cancer chemotherapy. The study also found that these combinations had protective effects against the toxicity typically caused by Dox. Especially notable was the increase in genes associated with tumor reduction and a decrease in those linked to cancer cell survival.
However, it’s essential to note that this study focused on the combined effects of vitamin D3, probiotics, and Dox, which makes it challenging to isolate the specific impact of vitamin D3 alone on breast cancer outcomes. Overall, the results suggest that incorporating vitamin D3 into breast cancer treatment protocols could be beneficial, particularly in combination with other agents.
Read More
9
EB1089 enhances HER2-positive treatments
We aimed to understand how EB1089, a vitamin D3 analog, influences the treatment of HER2-positive breast cancer when combined with established therapies like lapatinib and antiestrogens. In our research, we used two types of breast cancer cells—BT-474 and SK-BR-3—both of which are HER2-positive but have differing estrogen receptor statuses.
Our findings revealed that EB1089 significantly boosted the antiproliferative effects of lapatinib when used together with antiestrogens. Notably, in the SK-BR-3 cells, which are estrogen receptor-negative, EB1089 successfully restored the effectiveness of antiestrogen treatment. This shows that EB1089 plays a pivotal role in enhancing cell growth inhibition in HER2-positive breast cancer cells.
Additionally, we discovered that this analog modulated the expression of the estrogen receptor alpha protein and reduced Akt phosphorylation, contributing to its effects. Overall, our investigation highlights the potential of incorporating vitamin D3 analogs like EB1089 into existing cancer treatment regimens, opening new avenues for managing HER2-positive breast cancer more effectively.
Our findings revealed that EB1089 significantly boosted the antiproliferative effects of lapatinib when used together with antiestrogens. Notably, in the SK-BR-3 cells, which are estrogen receptor-negative, EB1089 successfully restored the effectiveness of antiestrogen treatment. This shows that EB1089 plays a pivotal role in enhancing cell growth inhibition in HER2-positive breast cancer cells.
Additionally, we discovered that this analog modulated the expression of the estrogen receptor alpha protein and reduced Akt phosphorylation, contributing to its effects. Overall, our investigation highlights the potential of incorporating vitamin D3 analogs like EB1089 into existing cancer treatment regimens, opening new avenues for managing HER2-positive breast cancer more effectively.
Read More
9
We investigated the potential impact of 1,25 dihydroxycholecalciferols, commonly known as vitamin D3, alongside genistein, a dietary phytoestrogen, on breast cancer cell lines, specifically MCF-7 and MDA-MB-231. Our research focused on their ability to inhibit cancer cell growth, progression, and metastasis, both individually and in combination.
Through a series of assays, including flow cytometry and cell invasion tests, we observed that vitamin D3 and genistein were effective in reducing cell proliferation. Notably, they prompted the cancer cells to enter a resting phase and triggered the process of apoptosis, or programmed cell death. We found that this was linked to increased expression of certain genes like BAX and CASP3 and decreased levels of the BCL-2 gene, a key player in cell survival.
Interestingly, both compounds also showed promise in curbing metastasis. They enhanced the expression of E-cadherin, a protein that helps cells stick together, while reducing the expression of other proteins associated with cancer spread. Furthermore, these treatments also positively influenced key protein expressions that enhance cancer response and overall survivability.
Ultimately, our findings suggest that vitamin D3, especially in combination with genistein, holds potential as a candidate for breast cancer treatment. However, given the combined approach, isolating the effects of vitamin D3 alone remains challenging, which adds complexity to our understanding.
Through a series of assays, including flow cytometry and cell invasion tests, we observed that vitamin D3 and genistein were effective in reducing cell proliferation. Notably, they prompted the cancer cells to enter a resting phase and triggered the process of apoptosis, or programmed cell death. We found that this was linked to increased expression of certain genes like BAX and CASP3 and decreased levels of the BCL-2 gene, a key player in cell survival.
Interestingly, both compounds also showed promise in curbing metastasis. They enhanced the expression of E-cadherin, a protein that helps cells stick together, while reducing the expression of other proteins associated with cancer spread. Furthermore, these treatments also positively influenced key protein expressions that enhance cancer response and overall survivability.
Ultimately, our findings suggest that vitamin D3, especially in combination with genistein, holds potential as a candidate for breast cancer treatment. However, given the combined approach, isolating the effects of vitamin D3 alone remains challenging, which adds complexity to our understanding.
Read More
9
Vitamin D3 inhibits breast cancer growth
We explored the role of vitamin D3, or cholecalciferol, in combating breast cancer through a comprehensive study involving breast cancer cell lines and a mouse model called Ehrlich ascites carcinoma (EAC). To understand how vitamin D3 might affect cancer, we monitored its effects on both estrogen receptor-positive and negative cell lines in vitro, noting that these cells absorbed around 50% of vitamin D3 during a 48-hour incubation period.
Our results showcased that vitamin D3 significantly slowed down the proliferation of breast cancer cells in a dose-dependent manner, with effective inhibitory concentrations ranging from 0.10 to 0.35 mM. Prolonged exposure didn’t seem to boost its effectiveness, suggesting an optimal treatment window. Notably, vitamin D3 prompted cell cycle arrest and apoptosis—two crucial mechanisms for controlling cancer growth—through the regulation of specific proteins like p53, cyclin-D1, and Bcl2.
Furthermore, vitamin D3 demonstrated its potential as an anti-angiogenic agent by impeding blood vessel growth both in vitro and during experiments with chorioallantoic membranes. In our in vivo approach, administering vitamin D3 intraperitoneally in mice led to reduced tumor growth and body weight gain.
Overall, the findings indicate that vitamin D3 can exert cytotoxic effects on breast cancer cells and may serve as a valuable player in cancer therapy strategies. This prompts further investigation into its therapeutic applications against breast cancer.
Our results showcased that vitamin D3 significantly slowed down the proliferation of breast cancer cells in a dose-dependent manner, with effective inhibitory concentrations ranging from 0.10 to 0.35 mM. Prolonged exposure didn’t seem to boost its effectiveness, suggesting an optimal treatment window. Notably, vitamin D3 prompted cell cycle arrest and apoptosis—two crucial mechanisms for controlling cancer growth—through the regulation of specific proteins like p53, cyclin-D1, and Bcl2.
Furthermore, vitamin D3 demonstrated its potential as an anti-angiogenic agent by impeding blood vessel growth both in vitro and during experiments with chorioallantoic membranes. In our in vivo approach, administering vitamin D3 intraperitoneally in mice led to reduced tumor growth and body weight gain.
Overall, the findings indicate that vitamin D3 can exert cytotoxic effects on breast cancer cells and may serve as a valuable player in cancer therapy strategies. This prompts further investigation into its therapeutic applications against breast cancer.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Side effects manageable
4 people found this helpful
I read about vitamin D possibly reducing the side effects of the drug Arimidex (anastrozole), which I take daily for estrogen-positive breast cancer. My oncologist is pleased that I am managing the side effects, and I believe that taking 5000 IUs of Vitamin D3 daily contributes to that. Some women in my support group have had to stop Arimidex due to side effects, so I hope this helps me prevent that. I am 65 days in and tolerating it well, which is reassuring given my previous chemotherapy side effects. Always consult with your doctor, of course.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Schömann-Finck M, Vogt T, Reichrath J. Umbrella Review on the Relationship Between Vitamin D Intake and Cancer. Anticancer Res. 2025;45:855. doi:10.21873/anticanres.17474
- Soni D, Tiwari A, Kushwah PS, Dubey S, Khan S. Levels of Serum 25-Hydroxy Vitamin D in Benign and Malignant Breast Disease Patients: An Observational Study. Cureus. 2025;17:e78283. doi:10.7759/cureus.78283
- Pereira da Silva Garcia MR, Rechinelli AB, Minto Dos Santos D, Abdala Nogueira Souza J, Barcellos Leite da Silva L, et al. Low Serum Vitamin D Levels Are Associated with Reduced Muscle Strength in Women with Breast Cancer. Nutr Cancer. 2025. doi:10.1080/01635581.2025.2471621
- Hutajulu SH, Aresy S, Astari YK, Wiranata JA, Puspitaningtyas H, et al. Severe Deficiency of Vitamin D and Anthracycline-Taxane Regimen are associated with Cachexia Following Breast Cancer Chemotherapy: A Single Center Assessment Using Two Consensus-Based Criteria. Asian Pac J Cancer Prev. 2025;26:189. doi:10.31557/APJCP.2025.26.1.189
- Momivand M, Razaghi M, Mohammadi F, Hoseinzadeh E, Najafi-Vosough R. The status of serum 25(OH)D levels is related to breast cancer. Cancer Treat Res Commun. 2024;42:100870. doi:10.1016/j.ctarc.2025.100870
- Shu C, Yang Q, Huang J, Xie X, Li H, et al. Pretreatment plasma vitamin D and response to neoadjuvant chemotherapy in breast cancer: evidence from pooled analysis of cohort studies. Int J Surg. 2024;110:8126. doi:10.1097/JS9.0000000000002142
- Gao C, Jian C, Wang L, Liu Y, Xiong Y, et al. FAP-targeting biomimetic nanosystem to restore the activated cancer-associated fibroblasts to quiescent state for breast cancer radiotherapy. Int J Pharm. 2025;670:125190. doi:10.1016/j.ijpharm.2025.125190
- Ottaiano A, Facchini BA, Iacovino M, Santorsola M, Facchini S, et al. Impact of Vitamin D Levels on Progression-Free Survival and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16. doi:10.3390/cancers16244206
- Almassri HF, Abdul Kadir A, Srour M, Foo LH. The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial. Nutrients. 2024;16. doi:10.3390/nu16223960
- Bissan ADT, Amegonou AEH, Sidibé FM, Ly M, Barry NOK, et al. [Vitamin D Deficiency In Advanced Breast Cancer Risk In Mali]. Mali Med. 2024;39:50.
- Almassri HF, Abdul Kadir A, Srour M, Foo LH. The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial. Clin Nutr ESPEN. 2025;65:64. doi:10.1016/j.clnesp.2024.11.014
- Abdollahi S, Vahdat M, Saeedirad Z, Mahmoudi Z, Torkaman M, et al. Multifaceted Role of Vitamin D in Breast Cancer: A Systematic Review of Genetic and Pathway-Based Mechanisms. Asian Pac J Cancer Prev. 2024;25:3349. doi:10.31557/APJCP.2024.25.10.3349
- Wu S, Ma XD, Zhang XM, Shi C, Du KY, et al. Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER- breast cancer: A Mendelian randomization study. Medicine (Baltimore). 2024;103:e40262. doi:10.1097/MD.0000000000040262
- Yum C, Andolino C, Larrick B, Sheeley MP, Teegarden D. 1α,25-Dihydroxyvitamin D Downregulates Adipocyte Impact on Breast Cancer Cell Migration and Adipokine Release. Nutrients. 2024;16. doi:10.3390/nu16183153
- Stachowicz-Suhs M, Łabędź N, Milczarek M, Kłopotowska D, Filip-Psurska B, et al. Vitamin D reduces the expression of M1 and M2 macrophage markers in breast cancer patients. Sci Rep. 2024;14:22126. doi:10.1038/s41598-024-73152-x
- Tirgar A, Rezaei M, Ehsani M, Salmani Z, Rastegari A, et al. Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial. Sci Rep. 2024;14:21372. doi:10.1038/s41598-024-72172-x
- Zárate-Pérez A, Cruz-Cázares AP, Ordaz-Rosado D, García-Quiroz J, León-Del-Rio A, et al. The vitamin D analog EB1089 sensitizes triple-negative breast cancer cells to the antiproliferative effects of antiestrogens. Adv Med Sci. 2024;69:398. doi:10.1016/j.advms.2024.08.004
- Pereira TSS, Marques SSA, Olandoski M, Polakowski CB, Beltrame OC, et al. Vitamin D and Breast Cancer Risk: Evaluating the Association and Effective Risk Reduction. Breast Care (Basel). 2024;19:197. doi:10.1159/000539750
- Bernhardt SM, Ozaki MK, Betts C, Bleyle LA, DeBarber AE, et al. Altered liver metabolism post-wean abolishes efficacy of vitamin D for breast cancer prevention in a mouse model. bioRxiv. 2024. doi:10.1101/2024.05.28.596304
- McGuinness JE, Anderson GL, Mutasa S, Hershman DL, Terry MB, et al. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectr. 2024;8. doi:10.1093/jncics/pkae042
- Roy M, Hussain F. Mitigation of Breast Cancer Cells' Invasiveness via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles. Int J Mol Sci. 2024;25. doi:10.3390/ijms25105348
- Kim S, Chen N, Reid P. Current and future advances in practice: aromatase inhibitor-induced arthralgia. Rheumatol Adv Pract. 2024;8:rkae024. doi:10.1093/rap/rkae024
- Mirzadeh MA, Eslami M, Ghanbari A, Zarbakhsh S, Yosefi S, et al. Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects. Med Oncol. 2024;41:111. doi:10.1007/s12032-024-02346-0
- Achounna AS, Ordaz-Rosado D, García-Quiroz J, Morales-Guadarrama G, Milo-Rocha E, et al. EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells. Int J Mol Sci. 2024;25. doi:10.3390/ijms25063165
- Łabędź N, Anisiewicz A, Stachowicz-Suhs M, Banach J, Kłopotowska D, et al. Dual effect of vitamin D on breast cancer-associated fibroblasts. BMC Cancer. 2024;24:209. doi:10.1186/s12885-024-11961-z
- Stachowicz-Suhs M, Łabędź N, Anisiewicz A, Banach J, Kłopotowska D, et al. Calcitriol promotes M2 polarization of tumor-associated macrophages in 4T1 mouse mammary gland cancer via the induction of proinflammatory cytokines. Sci Rep. 2024;14:3778. doi:10.1038/s41598-024-54433-x
- Alatawi FS, Faridi U. Anticancer and anti-metastasis activity of 1,25 dihydroxycholecalciferols and genistein in MCF-7 and MDA-MB-231 breast cancer cell lines. Heliyon. 2023;9:e21975. doi:10.1016/j.heliyon.2023.e21975
- Tahmasebi M, Veissi M, Hosseini SA, Jamshidnezhad A. Effect of vitamin D supplementation on inflammatory markers and total antioxidant capacity in breast cancer women using a machine learning technique. Explor Target Antitumor Ther. 2023;4:1059. doi:10.37349/etat.2023.00180
- Veeresh PKM, Basavaraju CG, Dallavalasa S, Anantharaju PG, Natraj SM, et al. Vitamin D3 Inhibits the Viability of Breast Cancer Cells In Vitro and Ehrlich Ascites Carcinomas in Mice by Promoting Apoptosis and Cell Cycle Arrest and by Impeding Tumor Angiogenesis. Cancers (Basel). 2023;15. doi:10.3390/cancers15194833
